Objectif The project aims at developing, prototyping, validating and bringing to market a portable assay system for the pre-diabetes and diabetes diagnosis and control, consisting of a disposable medical device equipped with a Lab-on-Chip (LoC) used for Point of Care or Self-Monitoring of protein biomarkers in biological fluids, like Glycated Hemoglobin (HbA1c). The medical device relies on a unique technology for diagnosis via protein biomarkers analysis, comprising a separation and a labelling stage of target molecule to detect and quantify the amount of glycated Hemoglobin in a drop of blood. The way this diagnostic medical device has been conceived and designed makes it unique compared to other devices available in the market. It is based on a disposable chip, easy to use, which does not require qualified personnel assistance and minimises manipulation. Stable at room temperature both in storage and during use, it does not need external calibration. These characteristics, together with its low cost, make it an excellent option for the final user (patient, pharmacy, hospital, etc.). The proposed diagnostic medical device consists of a LoC based on breakthrough microelectromechanical systems for protein detection through the protein biomarkers analysis. Such medical device is cheaper (€2-3/device), faster (~10 minutes), more robust (to vibrations, to high/low temperatures), more durable (2 years ambient-stored) and more versatile (easy to use, software-programmable, smart-phone integrated) than the already available and the foreseen portable alternatives, while being as precise as the costlier laboratory solutions. The project is relevant to the selected WP because it regards an innovative medical device for diabetes and pre-diabetes, thus with diagnostic and prevention applications, based on a solid feasibility study and a business plan. The project intends to bring the medical device from TRL7 to market.In addition, it already got the EC’s Seal of Excellence in 2015 Champ scientifique engineering and technologyother engineering and technologiesmicrotechnologylab on a chipnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineendocrinologydiabetesengineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phonesmedical and health sciencesbasic medicinepharmacology and pharmacy Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Thème(s) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-2-2016-2017 Régime de financement SME - SME instrument Coordinateur DIANAX SRL Contribution nette de l'UE € 2 171 137,00 Adresse VIALE ORTLES 22/24 20139 MILANO Italie Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Nord-Ovest Lombardia Milano Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 3 116 913,25
